The DOI matches its Crossref record; 94 of the 94 references it cites were found in a registry or an index.
An open label, non-randomized study assessing a prebiotic fiber intervention in a small cohort of Parkinson’s disease participants
Open accessAbstract
A pro-inflammatory intestinal microbiome is characteristic of Parkinson’s disease (PD). Prebiotic fibers change the microbiome and this study sought to understand the utility of prebiotic fibers for use in PD patients. The first experiments demonstrate that fermentation of PD patient stool with prebiotic fibers increased the production of beneficial metabolites (short chain fatty acids, SCFA) and changed the microbiota demonstrating the capacity of PD microbiota to respond favorably to prebiotics. Subsequently, an open-label, non-randomized study was conducted in newly diagnosed, non-medicated ( n = 10) and treated PD participants ( n = 10) wherein the impact of 10 days of prebiotic intervention was evaluated. Outcomes demonstrate that the prebiotic intervention was well tolerated (primary outcome) and safe (secondary outcome) in PD participants and was associated with beneficial biological changes in the microbiota, SCFA, inflammation, and neurofilament light chain. Exploratory analyses indicate effects on clinically relevant outcomes. This proof-of-concept study offers the scientific rationale for placebo-controlled trials using prebiotic fibers in PD patients. ClinicalTrials.gov Identifier: NCT04512599.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A proof-of-concept trial conducted in PD patients has demonstrated that SCFAs-promoting prebiotic fiber intervention reduced plasma zonulin, indicating improved intestinal barrier integrity.”
From Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases (2024) · cites this paper as [332]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“There is limited evidence of how pre- and pro-biotics influence gut microbiome composition and functionality, with only limited evidence from a few open-label studies to suggest that pre- and pro-biotics can increase the abundance of SCFA-producing bacteria, reduce the abundance of pro-inflammatory bacteria, and reduce levels of intestinal inflammatory markers like calprotectin [163, 177].”
From The gut–brain axis in early Parkinson’s disease: from prodrome to prevention (2025) · cites this paper as [177]
Experimental — accuracy not yet measuredIn the citing paper
“Importantly, the trial reported an increased abundance of SCFAs-producing species and increased plasma SCFA levels, along with improved intestinal barrier integrity and reduced intestinal inflammation.332”
From Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases (2024) · cites this paper as [332]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The SILVA ribosomal RNA gene database project: improved data processing and web-based tools
Quast, C., Pruesse, E., Yilmaz, P., Gerken, J., Schweer, T., Yarza, P., Peplies, J., & Glöckner, F. O. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks1219 · Cited by 33,055
Parkinsonism: onset, progression, and mortality
Hoehn, M. M., & Yahr, M. D. (1967) · Neurology · doi:10.1212/wnl.17.5.427 · Cited by 12,107
Hughes, A. J., Daniel, S. E., Kilford, L., & Lees, A. J. (1992) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.55.3.181 · Cited by 10,378
Overdependence on degraded gist memory in Alzheimer's disease.
Gallo, D. A., Shahid, K. R., Olson, M. A., Solomon, T. M., Schacter, D. L., & Budson, A. E. (2006) · Neuropsychology · doi:10.1037/0894-4105.20.6.625 · Cited by 4,757
da Luz, A. C. D. D. S., Dias, G. P., Bevilaqua, M. C. D. N., Cocks, G. D., Gardino, P. F., Thuret, S., & Nardi, A. E. (2013) · Neuropsychobiology · doi:10.1159/000353269 · Cited by 4,015
Interaction between microbiota and immunity in health and disease
Zheng, D., Liwinski, T., & Elinav, E. (2020) · Cell Research · doi:10.1038/s41422-020-0332-7 · Cited by 3,947
Distance‐Based Tests for Homogeneity of Multivariate Dispersions
Anderson, M. J. (2006) · Biometrics · doi:10.1111/j.1541-0420.2005.00440.x · Cited by 3,304
Beghini, F., McIver, L. J., Blanco-Míguez, A., Dubois, L., Asnicar, F., Maharjan, S., Mailyan, A., Manghi, P., Scholz, M., Thomas, A. M., et al. (2021) · eLife · doi:10.7554/elife.65088 · Cited by 2,303
Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration
Qin, L., Wu, X., Block, M. L., Liu, Y., Breese, G. R., Hong, J., Knapp, D. J., & Crews, F. T. (2007) · Glia · doi:10.1002/glia.20467 · Cited by 2,144
Gut microbiota are related to Parkinson's disease and clinical phenotype
Scheperjans, F., Aho, V., Pereira, P. A. B., Koskinen, K., Paulin, L., Pekkonen, E., Haapaniemi, E., Kaakkola, S., Eerola‐Rautio, J., Pohja, M., et al. (2015) · Movement Disorders · doi:10.1002/mds.26069 · Cited by 1,968
Dhariwal, A., Chong, J., Habib, S. M., King, I. L., Agellon, L. B., & Xia, J. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx295 · Cited by 1,946
Chong, J., Liu, P., Zhou, G., & Xia, J. (2020) · Nature Protocols · doi:10.1038/s41596-019-0264-1 · Cited by 1,708
Schröder, H., Fitó, M., Estruch, R., Martínez-González, M. A., Corella, D., Salas-Salvadó, J., Lamuela-Raventós, R., Ros, E., Salaverría, I., Fiol, M., et al. (2011) · The Journal of Nutrition · doi:10.3945/jn.110.135566 · Cited by 1,624
SCFA: mechanisms and functional importance in the gut
Martin‐Gallausiaux, C., Marinelli, L., Blottière, H. M., Larraufie, P., & Lapaque, N. (2020) · Proceedings of The Nutrition Society · doi:10.1017/s0029665120006916 · Cited by 1,585
Colonic bacterial composition in Parkinson's disease
Keshavarzian, A., Green, S. J., Engen, P. A., Voigt, R. M., Naqib, A., Forsyth, C. B., Mutlu, E., & Shannon, K. M. (2015) · Movement Disorders · doi:10.1002/mds.26307 · Cited by 1,281
Self-citationUnger, M. M., Spiegel, J., Dillmann, K.-U., Grundmann, D., Philippeit, H., Bürmann, J., Faßbender, K., Schwiertz, A., & Schäfer, K.-H. (2016) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2016.08.019 · Cited by 1,159
Forsyth, C. B., Shannon, K. M., Kordower, J. H., Voigt, R. M., Shaikh, M., Jaglin, J. A., Estes, J. D., Dodiya, H. B., & Keshavarzian, A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028032 · Cited by 974
Self-citationHill‐Burns, E. M., Debelius, J. W., Morton, J. T., Wissemann, W. T., Lewis, M. R., Wallen, Z. D., Peddada, S. D., Factor, S. A., Molho, E., Zabetian, C. P., et al. (2017) · Movement Disorders · doi:10.1002/mds.26942 · Cited by 874
Discovery and inhibition of an interspecies gut bacterial pathway for Levodopa metabolism
Maini Rekdal, V., Bess, E. N., Bisanz, J. E., Turnbaugh, P. J., & Balskus, E. P. (2019) · Science · doi:10.1126/science.aau6323 · Cited by 753
Brain‐derived neurotrophic factor and the development of structural neuronal connectivity
Cohen‐Cory, S., Kidane, A. H., Shirkey, N. J., & Marshak, S. (2010) · Developmental Neurobiology · doi:10.1002/dneu.20774 · Cited by 611
Hamaker, B. R., & Tuncil, Y. E. (2014) · Journal of Molecular Biology · doi:10.1016/j.jmb.2014.07.028 · Cited by 601
Self-citationEstaki, M., Jiang, L., Bokulich, N. A., McDonald, D. T., González, A., Kościółek, T., Martino, C., Zhu, Q., Birmingham, A., Vázquez‐Baeza, Y., et al. (2020) · Current Protocols in Bioinformatics · doi:10.1002/cpbi.100 · Cited by 588
Intestinal dysbiosis and lowered serum lipopolysaccharide-binding protein in Parkinson's disease
Hasegawa, S., Goto, S., Tsuji, H., Okuno, T., Asahara, T., Nomoto, K., Shibata, A., Fujisawa, Y., Minato, T., Okamoto, A., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0142164 · Cited by 523
van Kessel, S. P., Frye, A. K., El-Gendy, A. O., Castejon, M., Keshavarzian, A., van Dijk, G., & El Aidy, S. (2019) · Nature Communications · doi:10.1038/s41467-019-08294-y · Cited by 521
Self-citationSturgeon, C., & Fasano, A. (2016) · Tissue Barriers · doi:10.1080/21688370.2016.1251384 · Cited by 497
Hepatocytes: a key cell type for innate immunity
Zhou, Z., Xu, M.-J., & Gao, B. (2016) · Cellular & Molecular Immunology · doi:10.1038/cmi.2015.97 · Cited by 472
Power and sample-size estimation for microbiome studies using pairwise distances and PERMANOVA
Kelly, B. J., Gross, R., Bittinger, K. L., Sherrill-Mix, S. A., Lewis, J. D., Collman, R. G., Bushman, F. D., & Li, H. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btv183 · Cited by 467
Prebiotics: why definitions matter
Hutkins, R. W., Krumbeck, J. A., Bindels, L. B., Cani, P. D., Fahey, G. C., Jr., Goh, Y. J., Hamaker, B. R., Martens, E. C., Mills, D. A., Rastal, R. A., et al. (2015) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2015.09.001 · Cited by 460
Self-citationThe endotoxin hypothesis of neurodegeneration
Brown, G. C. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1564-7 · Cited by 457
Inflammatory and Microbiota-Related Regulation of the Intestinal Epithelial Barrier
Barbara, G., Barbaro, M. R., Fuschi, D., Palombo, M., Falangone, F., Cremon, C., Marasco, G., & Stanghellini, V. (2021) · Frontiers in Nutrition · doi:10.3389/fnut.2021.718356 · Cited by 446
Dysbiosis of gut microbiota and microbial metabolites in Parkinson's disease
Sun, M.-F., & Shen, Y.-Q. (2018) · Ageing Research Reviews · doi:10.1016/j.arr.2018.04.004 · Cited by 445
Ryu, J., Kim, S. J., Rah, S.-H., Kang, J. I., Jung, H. E., Lee, D., Lee, H. K., Lee, J., Park, B. S., Yoon, T., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.11.007 · Cited by 437
Aho, V. T. E., Houser, M. C., Pereira, P. A. B., Chang, J., Rudi, K., Paulin, L., Hertzberg, V., Auvinen, P., Tansey, M. G., & Scheperjans, F. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00427-6 · Cited by 435
Bacioglu, M., Maia, L. F., Preische, O., Schelle, J., Apel, A., Kaeser, S. A., Schweighauser, M., Eninger, T., Lambert, M., Pilotto, A., et al. (2016) · Neuron · doi:10.1016/j.neuron.2016.05.018 · Cited by 435
Lively, S. S., & Schlichter, L. C. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00215 · Cited by 411
Zonulin, regulation of tight junctions, and autoimmune diseases
Fasano, A. (2012) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2012.06538.x · Cited by 365
Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression
Aho, V. T. E., Pereira, P. A. B., Voutilainen, S., Paulin, L., Pekkonen, E., Auvinen, P., & Scheperjans, F. (2019) · eBioMedicine · doi:10.1016/j.ebiom.2019.05.064 · Cited by 361
Gao, H.-M., Zhang, F., Zhou, H., Kam, W., Wilson, B., & Hong, J.-S. (2011) · Environmental Health Perspectives · doi:10.1289/ehp.1003013 · Cited by 355
Schwiertz, A., Spiegel, J., Dillmann, U., Grundmann, D., Bürmann, J., Faßbender, K., Schäfer, K.-H., & Unger, M. M. (2018) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2018.02.022 · Cited by 318
Paudel, Y. N., Shaikh, M. F., Chakraborti, A., Kumari, Y., Aledo-Serrano, Á., Aleksovska, K., Alvim, M. K. M., & Othman, I. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00628 · Cited by 311
Self-citationStructural alterations of the intestinal epithelial barrier in Parkinson’s disease
Clairembault, T., Leclair‐Visonneau, L., Coron, E., Bourreille, A., Dily, S. L., Vavasseur, F., Heymann, M., Neunlist, M., & Derkinderen, P. (2015) · Acta Neuropathologica Communications · doi:10.1186/s40478-015-0196-0 · Cited by 305
Spiegel, B. M. R., Hays, R. D., Bolus, R. R., Melmed, G., Chang, L., Whitman, C. B., Khanna, P. P., Paz, S. H., Hays, T., Reise, S. P., et al. (2014) · The American Journal of Gastroenterology · doi:10.1038/ajg.2014.237 · Cited by 272
Gastrointestinal Effects of Low-Digestible Carbohydrates
Grabitske, H. A., & Slavin, J. L. (2009) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408390802067126 · Cited by 267
Association between diabetes and subsequent Parkinson disease: A record-linkage cohort study
De Pablo-Fernandez, E., Goldacre, R., Pakpoor, J., Noyce, A. J., & Warner, T. T. (2018) · Neurology · doi:10.1212/wnl.0000000000005771 · Cited by 242
Gutsmann, T., Müller, M., Carroll, S. F., MacKenzie, R. C., Wiese, A., & Seydel, U. (2001) · Infection and Immunity · doi:10.1128/iai.69.11.6942-6950.2001 · Cited by 229
Schumann, R. R., Kirschning, C. J., Unbehaun, A., Aberle, H., Knopf, H. P., Lamping, N., Ulevitch, R. J., & Herrmann, F. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.7.3490 · Cited by 219
Naqib, A. D., Poggi, S., Wang, W., Hyde, M., Kunstman, K., & Green, S. J. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7834-2_7 · Cited by 212
Self-citationValidation of Serum Neurofilament Light Chain as a Biomarker of Parkinson's Disease Progression
Mollenhauer, B., Dakna, M., Kruse, N., Galasko, D. R., Foroud, T., Zetterberg, H., Schade, S., Gera, R. G., Wang, W., Gao, F., et al. (2020) · Movement Disorders · doi:10.1002/mds.28206 · Cited by 201
Plasma Markers of Disrupted Gut Permeability in Severe COVID-19 Patients
Giron, L. B., Dweep, H., Yin, X., Wang, H., Damra, M., Goldman, A. R., Gorman, N., Palmer, C. S., Tang, H., Shaikh, M. W., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.686240 · Cited by 194
Self-citationRose, D. J., DeMeo, M. T., Keshavarzian, A., & Hamaker, B. R. (2008) · Nutrition Reviews · doi:10.1111/j.1753-4887.2007.tb00282.x · Cited by 181
Self-citationGut Microbiota Differs Between Parkinson’s Disease Patients and Healthy Controls in Northeast China
Li, C., Cui, L., Yang, Y., Miao, J., Zhao, X., Zhang, J., Cui, G., & Zhang, Y. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00171 · Cited by 178
Parkinson’s Disease and the Gastrointestinal Microbiome
Lubomski, M., Tan, A. H., Lim, S.-Y., Holmes, A. J., Davis, R. L., & Sue, C. M. (2020) · Journal of Neurology · doi:10.1007/s00415-019-09320-1 · Cited by 172
Parkinson’s Disease and Gut Microbiota
Hirayama, M., & Ohno, K. (2021) · Annals of Nutrition and Metabolism · doi:10.1159/000518147 · Cited by 158
Theede, K., Holck, S., Ibsen, P. H., Ladelund, S., Nordgaard-Lassen, I., & Nielsen, A. M. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2015.05.038 · Cited by 158
Moonsamy, P. V., Williams, T., Bonella, P., Holcomb, C. L., Hoglund, B. N., Hillman, G. R., Goodridge, D., Turenchalk, G. S., Blake, L. A., Daigle, D. A., et al. (2013) · Tissue Antigens · doi:10.1111/tan.12071 · Cited by 158
Inflammatory bowel disease and Parkinson’s disease: common pathophysiological links
Lee, H.-S., Lobbestael, E., Vermeire, S., Sabino, J., & Cleynen, I. (2021) · Gut · doi:10.1136/gutjnl-2020-322429 · Cited by 151
Metabolic syndrome and risk of Parkinson disease: A nationwide cohort study
Nam, G. E., Kim, S. M., Han, K., Kim, N. H., Chung, H. S., Kim, J. W., Han, B., Cho, S.-J., Yu, J. H., Park, Y. G., et al. (2018) · PLoS Medicine · doi:10.1371/journal.pmed.1002640 · Cited by 148
Clinical value of fecal calprotectin
Ricciuto, A., & Griffiths, A. M. (2019) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2019.1619159 · Cited by 144
Interaction of Oxidative Stress and Misfolded Proteins in the Mechanism of Neurodegeneration
Abramov, A. Y., Potapova, E., Владимирович, Д. В., & Dunaev, A. (2020) · Life · doi:10.3390/life10070101 · Cited by 129
Regulation of common neurological disorders by gut microbial metabolites
Park, J., & Kim, C. H. (2021) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00703-x · Cited by 126
Tunçil, Y. E., Nakatsu, C. H., Kazem, A. E., Arıoğlu-Tuncil, S., Reuhs, B. L., Martens, E. C., & Hamaker, B. R. (2017) · Journal of Functional Foods · doi:10.1016/j.jff.2017.03.001 · Cited by 124
Self-citationGut Vibes in Parkinson's Disease: The Microbiota‐Gut‐Brain Axis
Bullich‐Vilarrubias, C., Keshavarzian, A., Garssen, J., Kraneveld, A. D., & Perez‐Pardo, P. (2019) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.12840 · Cited by 120
Self-citationMulak, A., Koszewicz, M., Panek-Jeziorna, M., Koziorowska-Gawron, E., & Budrewicz, S. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00992 · Cited by 110
The gut microbiome in Parkinson's disease: A culprit or a bystander?
Keshavarzian, A., Engen, P. A., Bonvegna, S., & Cilia, R. (2020) · Progress in brain research · doi:10.1016/bs.pbr.2020.01.004 · Cited by 108
Self-citationBacioglu, M., Maia, L. F., Preische, O., Schelle, J., Apel, A., Kaeser, S. A., Schweighauser, M., Eninger, T., Lambert, M., Pilotto, A., et al. (2016) · Neuron · doi:10.1016/j.neuron.2016.07.007 · Cited by 108
Nuzum, N. D., Loughman, A., Szymlek-Gay, E. A., Hendy, A., Teo, W.-P., & Macpherson, H. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.02.003 · Cited by 103 · cited 1×
“5 times normal, (4) abnormal liver function defined by ALT/AST > 4 times normal or elevated bilirubin, (5) antibiotic use within the 12 weeks prior to enrollment, (6) consumption of probiotics, prebiotics, or synbiotics within four weeks prior to enrollment, (7) consumption of a non-standard diet (e.”
BackgroundDumitrescu, L., Marta, D., Dănău, A., Lefter, A., Tulbă, D., Cozma, L., Manole, E., Gherghiceanu, M., Ceafalan, L. C., & Popescu, B. O. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.689723 · Cited by 100
The Intestinal Barrier in Parkinson’s Disease: Current State of Knowledge
van IJzendoorn, S. C. D., & Derkinderen, P. (2019) · Journal of Parkinson’s Disease · doi:10.3233/jpd-191707 · Cited by 97
Constipation: an emerging risk factor for Parkinson's disease?
Stirpe, P., Hoffman, M., Badiali, D., & Colosimo, C. (2016) · European Journal of Neurology · doi:10.1111/ene.13082 · Cited by 94
Tolerance to low-digestible carbohydrates: symptomatology and methods
Marteau, P. R., & Flourié, B. (2001) · British Journal Of Nutrition · doi:10.1079/bjn2000258 · Cited by 93
Engen, P. A., Zaferiou, A. M., Rasmussen, H. E., Naqib, A. D., Green, S. J., Fogg, L., Forsyth, C. B., Raeisi, S., Hamaker, B. R., & Keshavarzian, A. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00978 · Cited by 90
Self-citationSerum level of brain-derived neurotrophic factor in Parkinson's disease: a meta-analysis
Jiang, L., Zhang, H., Wang, C., Ming, F., Shi, X., & Yang, M. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2018.07.010 · Cited by 88
Potential of Prebiotic Butyrogenic Fibers in Parkinson's Disease
Cantu-Jungles, T. M., Rasmussen, H. E., & Hamaker, B. R. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.00663 · Cited by 86
Self-citationGut–Brain Axis as a Pathological and Therapeutic Target for Neurodegenerative Disorders
Toledo, A. R. L., Monroy, G. R., Salazar, F. E., Lee, J.-Y., Jain, S., Yadav, H., & Borlongan, C. V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031184 · Cited by 83
Review: The Role of Intestinal Dysbiosis in Parkinson’s Disease
Huang, Y., Liao, J., Liu, X., Zhong, Y., Cai, X., & Long, L. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.615075 · Cited by 79
Physical Inaccessibility of a Resistant Starch Shifts Mouse Gut Microbiota to Butyrogenic Firmicutes
Kaur, A., Chen, T., Green, S. J., Mutlu, E., Martin, B. R., Rumpagaporn, P., Patterson, J. A., Keshavarzian, A., & Hamaker, B. R. (2019) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201801012 · Cited by 77
Self-citationMassier, L., Chakaroun, R., Kovacs, P. L., & Heiker, J. T. (2020) · Gut · doi:10.1136/gutjnl-2020-323026 · Cited by 76
Serum zonulin is elevated in IBS and correlates with stool frequency in IBS‐D
Singh, P., Silvester, J. A., Chen, X., Xu, H. J., Sawhney, V., Rangan, V., Iturrino, J., Nee, J. W., Duerksen, D. R., & Lembo, A. J. (2019) · United European Gastroenterology Journal · doi:10.1177/2050640619826419 · Cited by 71
Cantu-Jungles, T. M., Ruthes, A. C., El-Hindawy, M., Moreno, R. B., Zhang, X., Cordeiro, L. M. C., Hamaker, B. R., & Iacomini, M. (2017) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2017.12.020 · Cited by 69
Self-citationPal, G. D., Shaikh, M., Forsyth, C. B., Ouyang, B., Keshavarzian, A., & Shannon, K. M. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00306 · Cited by 57
Self-citationPalermo, G., Mazzucchi, S., Vecchia, A. D., Siciliano, G., Bonuccelli, U., Azuar, C., Ceravolo, R., Lista, S., Hampel, H. J., & Baldacci, F. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-02035-9 · Cited by 55
Quantitative analysis of short-chain fatty acids in human plasma and serum by GC–MS
Yao, L., Davidson, E. A., Shaikh, M. W., Forsyth, C. B., Prenni, J. E., & Broeckling, C. D. (2022) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-021-03785-8 · Cited by 49
Self-citationDemir, E., Ozkan, H., Seçkin, K. D., Sahtiyancı, B., Demir, B., Tabak, Ö., Kumbasar, A., & Uzun, H. (2019) · Biomolecules · doi:10.3390/biom9010024 · Cited by 48
Cross-Sectional Study on the Gut Microbiome of Parkinson’s Disease Patients in Central China
Mao, L., Zhang, Y., Tian, J., Sang, M., Zhang, G., Zhou, Y., & Wang, P. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.728479 · Cited by 45
Chen, K., Chaou, C., Jiang, J., Yu, H.-W., Meng, Y.-H., Tang, W.-C., & Wu, C. (2016) · PLoS ONE · doi:10.1371/journal.pone.0153188 · Cited by 45
Faecal Transplantation, Pro- and Prebiotics in Parkinson’s Disease; Hope or Hype?
van Laar, T., Boertien, J. M., & Herranz, A. H. (2019) · Journal of Parkinson s Disease · doi:10.3233/jpd-191802 · Cited by 43
The impact of indigenous microbes on Parkinson's disease
Sampson, T. R. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.03.014 · Cited by 41
Papel de la microbiota intestinal en el desarrollo de diferentes enfermedades neurológicas
Castillo-Álvarez, F., & Marzo-Sola, M. E. (2019) · Neurología · doi:10.1016/j.nrl.2019.03.017 · Cited by 40
Role of the gut microbiota in the development of various neurological diseases
Castillo-Álvarez, F., & Marzo-Sola, M. E. (2021) · Neurología (English Edition) · doi:10.1016/j.nrleng.2019.03.026 · Cited by 40
A Novel Pathway for Microbial Metabolism of Levodopa
Jameson, K. G., & Hsiao, E. Y. (2019) · Nature Medicine · doi:10.1038/s41591-019-0544-x · Cited by 35
Zonulin measurement conundrum: add confusion to confusion does not lead to clarity
Fasano, A. (2020) · Gut · doi:10.1136/gutjnl-2020-323367 · Cited by 35
Microbes and Parkinson’s disease: from associations to mechanisms
Cannon, T., & Gruenheid, S. (2022) · Trends in Microbiology · doi:10.1016/j.tim.2022.01.004 · Cited by 33
Gut brain axis: an insight into microbiota role in Parkinson’s disease
Moustafa, S. A., Abdou, S. M., Dawood, A. S., Azar, J., Elmorsy, E. M., Rizk, N., & Salama, M. (2021) · Metabolic Brain Disease · doi:10.1007/s11011-021-00808-2 · Cited by 32
Plasma Lipopolysaccharide-Binding Protein Reflects Risk and Progression of Parkinson’s Disease
Chen, S.-J., Chi, Y., Ho, C.-H., Yang, W., & Lin, C. (2021) · Journal of Parkinson s Disease · doi:10.3233/jpd-212574 · Cited by 20
Cited by
Sorted by citations
Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases
Loh, J. S., Mak, W. Q., Tan, L. K. S., Ng, C. X., Chan, H. H., Yeow, S. H., Foo, J. B., Ong, Y. S., How, C. W., & Khaw, K. Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01743-1 · Cited by 1,193
Probiotics, prebiotics, and postbiotics in health and disease
Ji, J., Jin, W., Liu, S., Jiao, Z., & Li, X. (2023) · MedComm · doi:10.1002/mco2.420 · Cited by 449
Parkinson’s disease and gut microbiota: from clinical to mechanistic and therapeutic studies
Zhang, X., Tang, B., & Guo, J. (2023) · Translational Neurodegeneration · doi:10.1186/s40035-023-00392-8 · Cited by 212
Elkrief, A., Pidgeon, R., Vareki, S. M., Messaoudene, M., Castagner, B., & Routy, B. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01211-7 · Cited by 99
An Update on Prebiotics and on Their Health Effects
Bevilacqua, A., Campaniello, D., Speranza, B., Racioppo, A., Sinigaglia, M., & Corbo, M. R. (2024) · Foods · doi:10.3390/foods13030446 · Cited by 97
Metadata
- Authors
- Hall, D. A., Voigt, R. M., Cantu-Jungles, T. M., Hamaker, B., Engen, P. A., Shaikh, M., Raeisi, S., Green, S. J., Naqib, A., Forsyth, C. B., Chen, T., Manfready, R., Ouyang, B., Rasmussen, H. E., Sedghi, S., Goetz, C. G., & Keshavarzian, A.
- Affiliations
- Rush University Medical Center (US)
- Nanchang University (CN)
- University of Nebraska–Lincoln (US)
- Mercer University (US)
- Corresponding author
- Keshavarzian, Ali
- ORCID
- Venue
- Nature Communications
- Published
- 2023-02-18
- Volume
- 14
- Issue
- 1
- Pages
- 926-926
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC9938693
- OpenAlex
- W4321328855
- Cited by
- 124
- References
- 94
- Citations by year
- 2026: 24 · 2025: 55 · 2024: 35 · 2023: 10
- FWCI
- 21.10
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Nature Communications (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Parkinson's Foundation
- National Institutes of Health (NIH-R01, AA026801)
- National Institute on Alcohol Abuse and Alcoholism (R24AA026801)
- National Institute on Aging (R01AG056653)
- NIH Clinical Center
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Nursing › Nutrition and Dietetics › Microbial Metabolites in Food Biotechnology
- Keywords
- Parkinson's disease, prebiotic fiber, gut microbiota, short-chain fatty acids, intestinal fermentation, neuroinflammation, neurofilament light chain, dietary intervention, gut-brain axis
- MeSH terms
- Gastrointestinal Microbiome, Fatty Acids, Volatile, Feces, Humans, Parkinson Disease, Prebiotics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review